GlaxoSmithKline: starts Phase III trial with lupus combo
(CercleFinance.com) - On Tuesday GSK said it had started a final-stage Phase III clinical trial on the combination of its systemic lupus erythematosus drug Benlysta with Roche's rituximab.
The British drugmaker thinks that both compounds have "different" but "potentially complementary" mechanisms of action.
Belimumab, a monoclonal antibody, is currently the only biologic medicine specifically approved to treat systemic lupus erythematosus, which is characterised by swollen joints, unexplained fever, skin rashes and damage to organs.
The study is set to be completed in 2021.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The British drugmaker thinks that both compounds have "different" but "potentially complementary" mechanisms of action.
Belimumab, a monoclonal antibody, is currently the only biologic medicine specifically approved to treat systemic lupus erythematosus, which is characterised by swollen joints, unexplained fever, skin rashes and damage to organs.
The study is set to be completed in 2021.
Copyright (c) 2018 CercleFinance.com. All rights reserved.